<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR53">
 <label>53.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Patnaik</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Kang</surname>
    <given-names>SP</given-names>
   </name>
   <name>
    <surname>Rasco</surname>
    <given-names>D</given-names>
   </name>
   <name>
    <surname>Papadopoulos</surname>
    <given-names>KP</given-names>
   </name>
   <name>
    <surname>Elassaiss-Schaap</surname>
    <given-names>J</given-names>
   </name>
   <name>
    <surname>Beeram</surname>
    <given-names>M</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors</article-title>
  <source>Clin Cancer Res</source>
  <year>2015</year>
  <volume>21</volume>
  <fpage>4286</fpage>
  <lpage>4293</lpage>
  <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-2607</pub-id>
  <?supplied-pmid 25977344?>
  <pub-id pub-id-type="pmid">25977344</pub-id>
 </element-citation>
</ref>
